Indication
Parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.
Medicine details
- Medicine name:
- palopegteriparatide (Yorvipath)
- SMC ID:
- SMC2887
- Pharmaceutical company
- Ascendis Pharma
- BNF chapter
- Endocrine system
- Submission type
- Full
- Publication due date:
- 12 October 2026
- SMC meeting date:
- 01 September 2026
- Patient group submission deadline:
- 06 July 2026